[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"VZW Cardiovascular Research Center Aalst\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":82},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100582509","phase-4-effect-of-beta-blockers-on-coronary-flow-and-resistance-in-patients-with-anoca-100582509",false,"NCT06864234","Effect of Beta-blockers on Coronary Flow and Resistance in Patients With ANOCA","Effect of Beta-blockers on Coronary Flow and Resistance in Patients With ANOCA: a Randomised, Placebo-controlled, Mechanistic Study","BEACON","Inclusion Criteria:\n\n* Patients undergoing diagnostic coronary angiography for suspected angina pectoris who are found to have ANOCA i.e. an FFR \\>0.80 and no diameter stenosis \\>50%\n* Normal, TIMI 3 flow at angiography\n* Stable haemodynamics\n\nExclusion Criteria:\n\n* Clinical signs or symptoms of congestive heart failure\n* Severe valvular heart disease requiring either surgical or percutaneous intervention\n* History of coronary artery bypass grafting\n* Tortuous coronary anatomy in which wire manipulation could be complex\n* Heart rate \\\u003C60 beats per minute\n* Systolic blood pressure \\\u003C100 mmHg\n* Unable to give consent\n* LVEF\\\u003C40%",true,"ALL","18 Years",{"count":21,"type":22},46,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The goal of this clinical trial is to learn whether beta-blockers can improve coronary blood flow and reduce resistance in patients with angina and no obstructive coronary arteries (ANOCA).\n\nThe main questions it aims to answer are:\n\n* Do beta-blockers improve coronary blood flow in patients with ANOCA?\n* Do beta-blockers reduce coronary microvascular resistance in these patients?\n\nResearchers will compare a beta-blocker to a placebo to see if the medication has measurable effects on coronary circulation.\n\nParticipants will:\n\n* Receive a beta-blocker or a placebo\n* Undergo specialized heart tests (such as coronary flow and resistance measurements) before and after treatment.",[28,29,30],"Coronary Arterial Disease (CAD)","Angina (Stable)","Microvascular Circulation",[32,33,34,35,36],"angina","coronary artery disease","absolute coronary flow","continuous intracoronary thermodilution","Beta-blockers","RECRUITING","2025-07-08",{"date":40,"type":41},"2025-07-14","ACTUAL",{"date":43,"type":41},"2025-07-03",{"date":45,"type":22},"2025-12-31",{"name":47,"class":48},"VZW Cardiovascular Research Center Aalst","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":49},"100565846","evaluation-of-the-impact-of-pulsed-field-ablation-on-autonomic-nervous-system-modulation-in-paroxysmal-atrial-fibrillation-100565846","NCT06647485","Evaluation of the Impact of Pulsed Field Ablation on Autonomic Nervous System Modulation in Paroxysmal Atrial Fibrillation","A Prospective Randomized Study for the Evaluation of the Impact of Point-by-Point Pulse Field Ablation on Autonomic Nervous System Modulation in Paroxysmal Atrial Fibrillation","GPfIRE","Inclusion Criteria:\n\n* Symptomatic Paroxysmal Atrial Fibrillation (AF) that terminates spontaneously or with intervention within 7 days of onset\n* Age range: 18-70 years\n* Willing and capable of providing informed consent\n* Able and willing to comply with all pre-, post-, and follow-up testing and requirements\n\nExclusion Criteria:\n\n* Previously diagnosed Persistent AF (\\> 7 days in duration)\n* Previous LA ablation\n* Previous cardiac surgery\n* Myocardial Infarction within the previous 3 months\n* Severely compromised Left Ventricular Ejection Fraction (LVEF\\<40%)\n* Presence of implanted pacemaker or Implantable Cardioverter-Defibrillator (ICD) or other implanted metal cardiac device that may interfere with the pulsed electric field energy\n* Acute illness, active systemic infection, or sepsis\n* Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation.\n* Severe mitral regurgitation\n* Woman who are pregnant, lactating, or who are planning to become pregnant during the course of the clinical investigation","70 Years",{"count":60,"type":22},105,[62],"NA","The objective of this clinical trial is to evaluate the impact of pulse field (PF) energy, both alone and in combination with radiofrequency (RF) energy, on vagal modulation during point-by-point pulmonary vein isolation (PVI) in patients with paroxysmal atrial fibrillation (PAF). The effect of PF energy on ganglionated plexi (GP) will be assessed using heart rate variability (HRV) as a surrogate marker. Participants will be randomized into three groups: the PF-only group and the Hybrid group (PF posterior\u002FRF anterior) as the experimental arms, and the RF-only group as the control arm. HRV will be measured before and 24 hours after the PVI procedure. Additionally, cardio and neuro biomarkers (Troponin and S100B) will be measured pre-procedure and 20 minutes post-ablation. All participants will be followed for 12 months, with 24-hour Holter-ECG evaluations scheduled at 3, 6, and 12 months after the initial ablation procedure.",[65,66],"Atrial Fibrillation (AF)","Paroxysmal AF",[68,69,70,71,72,73,74],"vagal modulation","ganglionated plexi","pulsed field","dual-energy focal ablation","paroxysmal atrial fibrillation","heart rate variability","pulmonary vein isolation",{"date":76,"type":41},"2025-07-10",{"date":78,"type":41},"2025-01-29",{"date":80,"type":22},"2026-12",{"name":47,"class":48},""]